RZ358 has demonstrated clinical proof-of-concept through Phase 2a studies. Rezolute plans to advance clinical development of RZ358 and has initiated a Phase 2b clinical trial of RZ358 in patients with congenital HI and expects final study data in 2H 2021.
Rezolute has completed a successful pre-IND meeting with the FDA and IND-enabling toxicology studies in preparation for a Phase 1 study of RZ402 in DME. The exact timing of IND filing and study initiation is currently unknown due to the ongoing COVID-19 pandemic.
Rezolute is committed to ensuring the safety of patients and volunteers who participate in any of our ongoing clinical trials. We strictly follow regulatory requirements to ensure the health and well-being of our participants at all times.